Deep-pocketed San Francisco biotech lands another infectious disease fighter

Former Biogen and Exelixis CEO George Scangos leads Vir, which is backed by $600 million to tackle infectious diseases.

Source: bizjournals.com Health Care:Biotechnology headlines - May 8, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news